Countries covered: Global
Antidepressants are currently the third-leading drug class by prescription revenues, generating estimated global sales of $17 billion in 2002. However, recent year-on-year growth levels slowed from 18% to just 5% following generic fluoxetine (Prozac) competitors entering the market space and a delay in new product launches.
Theta’s report tracks changes that are taking place in the industry and offers your organization a detailed and accurate analysis of the US and key world markets for prescription antidepressants, including current and future trends in key disease and product areas, and a review of leading products, pipeline compounds, and companies.
- Key areas covered in this report:
- Overview of depression and related disorders
- Prescription drug treatments on the market
- Drug treatments in development
- Market analysis
- World and U.S. market size estimates and projections, 2003-2007
- Projected compound annual growth rates (CAGRs), 2002-2007
- Historical market sizes (2002, 2001) as comparator data
- Market leader and competitor analyses
- Market opinions regarding future forecasts
- Market trends and opportunities
- Company profiles of major industry players
An essential strategic resource, Theta’s Antidepressants: World Prescription Drug Markets answer the following questions:
- What is the current and future size and growth rates prevailing in the global, US, and major regional antidepressants markets?
- Which product areas/leading products are driving current and future growth?
- Which pipeline compounds are likely to drive future growth?
- Who are the leading players/competitors, both currently and in the future?
- Which product areas/treatment indications hold the greatest unmet need revenue potential (e.g. SNRIs, NK-1, bipolar disorder)?
Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.
Related Reports:
Snapshots US Pharmaceuticals 2009
Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
Pharmaceutical Industry in the United States - Porter’s Five Forces Strategy Analysis
Pharmaceuticals Industry Report
Pharmaceutical Industry in Mexico
Commercial Insight: Antipsychotics - Revenues of depots and new agents will partially offset generic erosion
Antipsychotics Market Forecast
Substance Abuse & Mental Health Clinics in the US - Industry Market Research Report
Commercial Insight: Antidiabetics in Australia - Reimbursement status shapes novel classes
Psychiatric Hospitals in Australia - Industry Risk Rating Report
|
(0 items)
